EGFR突变肺癌脑膜转移奥希替尼加量治疗1例

EGFR mutation lung cancer with leptomeningeal metastasis treated with increased dosage of osimertinib:a case report

非小细胞肺癌(NSCLC)脑膜转移患者的生存期短,治疗方法有限。奥希替尼是第三代表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI),可高效抑制EGFR敏感突变和EGFR T790M耐药突变,同时对EGFR突变的NSCLC软脑膜转移患者也有很好的疗效。本文报道1例奥希替尼加量至160 mg·d-1治疗EGFR突变肺腺癌脑膜转移,为临床治疗NSCLC难治性软脑膜转移提供参考。

Non-small cell lung cancer(NSCLC)patients with leptomeningeal metastases(LM)have short survival and limited treatment.Osimertinib,the 3rd-generation epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI),can selectively and effectively inhibit both EGFR and T790M mutations.It also has shown promising activity in NSCLC patients with LM and EGFR mutation.Here we reported a case of successful treatment with an increase of osimertinib to 160 mg·d-1 for a NSCLC patient with LM and EGFR mutation,hoping to provide a reference for clinical NSCLC refractory LM.